Victoria Socha

DocwireNews

Management of renal anemia, a common complication of chronic kidney disease (CKD), has traditionally included injectable erythropoietin-stimulating agents (ESAs). However, concerns regarding the cardiovascular safety of ESAs among patients with CKD, as well as emerging erythropoietin resistance, have created a need for alternative therapies.The oral agent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has been shown to be effective in improving renal anemia. However, according to Hanxue Zhao, MD, and colleagues in China, the effects of HIF-PHIs among patients with nondialysis-dependent CKD (NDD-CKD) have yet to be supported by updated meta-analysis.The researchers conduced a systemic search and meta-analysis of clinical randomized controlled trials among patients with NDD-CKD treated with HIF-PHIs. The search included PubMed, EMBASE, and Cochrane databases through July 16, 2023. The primary outcomes of interest were hemoglobin levels postintervention and the ratio of hemoglobin responses.A total of 22 studies were included in the meta-analysis. The study cohorts included 7178 participants in the HIF-PHI group, 3501 in the ESA group, and 2533 in the placebo group. The results suggested that treatment with HIF-PHIs increased the level of hemoglobin and improved iron metabolism. HIF-PHIs were not inferior to ESAs in terms of safety.&ldquo;HIF-PHIs may be a convenient and safe alternative to ESAs in patients with NDD-CKD and anemia,&rdquo; the researchers said.Source:&nbsp;&nbsp; <a href="https://karger.com/ajn/article/doi/10.1159/000533753/863157/Maintaining-renin-angiotensin-aldosterone-system?searchresult=1" target="_blank" rel="noopener">Renal Failure</a>

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

HIF-PHIs for Renal Anemia in Patients With NDD-CKD

Anemia and Kidney Disease

The oral agent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has been shown to be effective in improving renal anemia. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe